<scp>PRAME</scp> expression is similar in scar and desmoplastic melanoma

Plotzke, Jaclyn M; Zoumberos, Nicholas; Hrycaj, Steven; Harms, Paul W.; Bresler, Scott C.; Chan, May P.

doi:10.1111/cup.14286

Cited by 12 publications

(14 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PRAME expression in reactive histiocytes, as well as in fibroblasts of scar tissue, may be a diagnostic pitfall. 9 In summary, although PRAME was expressed in the nuclei of histiocytes, it was not observed in the cytoplasm of either lipid-laden or non-lipid-laden histiocytes, which indicated that cytoplasmic PRAME expression is unrelated to intracytoplasmic lipid droplets. Further research will be required to elucidate the mechanisms underlying cytoplasmic PRAME expression.…”

Section: Discussionmentioning

confidence: 86%

“…Previously, nuclear PRAME expression had been reported in neoplastic and non-neoplastic cells other than melanoma [7][8][9] but not in histiocytes. However, Lezcano et al 10 described nuclear PRAME staining in some hematolymphoid cells within lymph nodes.…”

Section: Discussionmentioning

confidence: 97%

“…In our cohort, low‐ and high‐intensity nuclear PRAME expression was observed in both neoplastic and non‐neoplastic histiocytes. Previously, nuclear PRAME expression had been reported in neoplastic and non‐neoplastic cells other than melanoma 7–9 but not in histiocytes. However, Lezcano et al 10 described nuclear PRAME staining in some hematolymphoid cells within lymph nodes.…”

Section: Discussionmentioning

confidence: 97%

“…Some of those cells may have been histiocytes. PRAME expression in reactive histiocytes, as well as in fibroblasts of scar tissue, may be a diagnostic pitfall 9 …”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Investigation of PRAME expression in lipid‐laden and non‐lipid‐laden cutaneous histiocytes

et al. 2022

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 86%

Section: Discussionmentioning

confidence: 97%

Section: Discussionmentioning

confidence: 97%

“…Some of those cells may have been histiocytes. PRAME expression in reactive histiocytes, as well as in fibroblasts of scar tissue, may be a diagnostic pitfall 9 …”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Investigation of PRAME expression in lipid‐laden and non‐lipid‐laden cutaneous histiocytes

et al. 2022

View full text Add to dashboard Cite

“…Thus, PRAME seems to be a suitable target for the differentiation between benign and malignant melanocytic lesions of the skin. Its value in the diagnosis of neoplastic skin lesions has been evaluated for many different entities, such as melanocytic lesions of the nail [ 18 ], spitzoid neoplasms [ 15 ], desmoplastic melanoma [ 19 ], halo nevi [ 20 ], nevus-associated melanomas [ 21 ], metastatic melanoma [ 22 ], and uveal melanoma [ 23 ]. Googe et al reported a focal PRAME expression in 22% of benign nevi (29/134), whereas 80% of melanomas (95/119) were diffusely PRAME-positive [ 24 ].…”

Section: Discussionmentioning

confidence: 99%

Standardized Computer-Assisted Analysis of PRAME Immunoreactivity in Dysplastic Nevi and Superficial Spreading Melanomas

Koch

Erdmann

Berking

et al. 2023

IJMS

View full text Add to dashboard Cite

PRAME (PReferentially expressed Antigen in MElanoma) is a cancer testis antigen that is frequently expressed in melanoma compared to benign melanocytic proliferations and nevi. However, the interpretation of the intensity and distribution of PRAME immunostaining is not standardized a lot, which makes interpretation difficult. PRAME-stained histological slides of superficial spreading melanomas (SSM) and dysplastic nevi (DN) were digitized and analyzed using the digital pathology and image platform QuPath. t-tests and ROC AUCs were performed with SPSS. A p-value of <0.05 was used for statistical significance, and a ROC AUC score of >0.8 was considered a good result. A cut-off score was defined in an evaluation cohort and subsequently analyzed in an independent validation cohort. In total, 81 PRAME-stained specimens were included. The evaluation cohort included 32 (50%) SSM and 32 (50%) DN, and the mean of PRAME-positive cells/mm2 for the entire lesion was 455.3 (SD 428.2) in SSM and 60.5 (SD 130.1; p < 0.001) in DN. The ROC AUC of PRAME-positive cells of the entire lesion was 0.866, and in the epidermis it was 0.901. The defined cut-off score to distinguish between DN and SSM was 97.67 cells/mm2. In the validation cohort, 16 out of 17 cases (94.1%) were correctly classified by the cut-off score. The computer-aided assessment of PRAME immunostaining is a useful tool in dermatopathology to distinguish between DN and SSM. Lesions with a moderate expression and indifferent morphologic features will remain a challenge for dermatopathologists.

show abstract

Refining the application of PRAME—a useful marker in high CSD and acral melanoma subtypes

Wakefield,

O’Keefe,

Heffron

2023

Virchows Arch

View full text Add to dashboard Cite

PRAME expression is similar in scar and desmoplastic melanoma

Cited by 12 publications

References 12 publications

Investigation of PRAME expression in lipid‐laden and non‐lipid‐laden cutaneous histiocytes

Investigation of PRAME expression in lipid‐laden and non‐lipid‐laden cutaneous histiocytes

Standardized Computer-Assisted Analysis of PRAME Immunoreactivity in Dysplastic Nevi and Superficial Spreading Melanomas

Refining the application of PRAME—a useful marker in high CSD and acral melanoma subtypes

Contact Info

Product

Resources

About